Etanercept (Enbrel)
Soluble TNF-receptor-p75/Fc fusion protein (decoy receptor) binding TNF-alpha and TNF-beta. Shorter-acting than mAb TNF inhibitors; 50 mg SC weekly (or 25 mg twice weekly). Approved for RA, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, JIA. Biphasic disposition with terminal half-life ~70-100h. SC bioavailability ~60%. Less immunogenic than full antibodies but still carries TB/serious infection risk.
Projected serum levels — 50 mg, once daily
Maintenance schedule: 50 mg once daily (subcutaneous).
Loading schedule: 150 mg on day 1, then 50 mg once daily — reaching therapeutic levels sooner.
Modeled steady state after ~14 days: peak ≈ 295 mg, trough ≈ 291 mg body load. Population-based estimate over 33 days for a 50 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Biologic
- Route modeled
- Subcutaneous
- Model confidence
- inferred
- Half-life
- 4.3 days
- Common dose
- 50 mg
- Suggested maximum
- 50 mg/day
- Reference dose range
- 25–50 mg (single dose)
- Suggested cadence
- once daily
- Validated against
- 50 mg sc — Cmax 2.4 mg/L at 72 h
Documented interactions
-
watch
Infliximab (Remicade) + Etanercept (Enbrel)
Etanercept (Enbrel) and Infliximab (Remicade) both push the tnf alpha in the same direction.
Serum checks 1 modeled interaction pairings for etanercept (enbrel) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Pharmacokinetics, pharmacodynamics, and safety of etanercept in patients with rheumatoid arthritis
Early clinical PK study establishing etanercept's terminal half-life (~70h), SC bioavailability, and dose-proportional exposure in RA.
-
Clinical pharmacokinetics and pharmacodynamics of etanercept
Review summarizing population PK, biphasic disposition, and target-mediated clearance contribution for etanercept.
2 published studies referenced in the app, each with a plain-language summary.